Japanese cedar pollinosis
Conditions
Interventions
Two pranlukast capsules are orally administered after the meal 4 times ( 2 times before the exposure and 2 times after the exposure ). The study consists of 2 times exposure in OHIO Chamber at one w
Sponsors
TOPIC Study (Trial of OHIO Chamber-Pranlukast Inhibitory Effect for Cedar Exposure-)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Subjects must have at least a 2-year history of allergic symptoms during the Japanese cedar pollen season, such as sneezing, nasal discharge and nasal obstruction. 2) Subjects must have had blood tests within a 3 years showing positive CAP-RAST scores ( between 2 and 6 ) for Japanese cedar pollen. 3) Subjects must be appropriate to this study by the judgment of doctor. 4) Informed consent must be obtained from the subjects prior to study entry.
Exclusion criteria
Exclusion criteria: 1) Subjects with a polyp or deformity of the nose. 2) Subjects who used steroid drugs for injection within 6 months before the start of this study. 3) Subjects with systemic diseases ( asthma or tuberculosis ). 4) Subjects with build-up phase of immunotherapy to Japanese cedar pollen. 5) Subjects with pregnancy, lactation or potential pregnancy. 6) Subjects who are inappropriate to this study by the judgment of doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| nose and eye symptoms | — |
Secondary
| Measure | Time frame |
|---|---|
| the number of sneezing, the amount of nasal secretion, the manifestation time of nasal symptoms, nasal airway resistance, respiratory function and performance test( D-CAT ) | — |
Countries
Japan
Contacts
Public ContactMinoru Gotoh
Nippon Medical School Chiba Hokusoh Hospital Department of Otolaryngology
Outcome results
None listed